Screening of solution stability provides an early alert on potential liabilities of drug candidates so that strategies can be developed to overcome the challenges. A fully automated solution stability assay has been developed to accelerate traditional manual operation. The assay uses the advanced capabilities of a high-performance liquid chromatography instrument that is present in many pharmaceutical research laboratories. The samples are prepared automatically by a temperature-controlled autosampler. The samples are delivered to the stability matrices, mixed, incubated, and injected at selected time points during the reaction time course. This automated process occurs without operator intervention, thus allowing 96 experiments to be run with 0.5 h of a scientist's time compared to 8 h for the same study when performed manually. Automation not only eliminates the manual operation but also improves accuracy and throughput. The assay protocol has been optimized to achieve homogenous mixing and eliminate carryover. The assay is robust, flexible, and high throughput. It can be used to study stability for a large number of samples under multiple incubation conditions and has a wide range of applications in drug discovery and development, such as screening compound stability in biological assay media, obtaining a stability-pH profile, surveying compound stability in physiological fluids, and performing development forced degradation and excipient compatibility. (Journal of Biomolecular Screening 2006:40-47) Journal of Biomolecular Screening 11(1); 2006 www.sbsonline.org 43 FIG. 2. Scheme of automated solution stability assay. HPLC = high-performance liquid chromatography.
INTRODUCTION
S TABILITY IN SOLUTION is a fundamental property of successful drug candidates. [1] [2] [3] [4] At the drug discovery stage, when drug candidates are screened against biological targets, compounds need to have sufficient stability in the assay buffers for enzyme, receptor, or cell-based assays to reliably measure biological activity. 5, 6 During oral dosing into living systems, compounds are challenged by acidic, basic, and enzymatic conditions in the gastrointestinal tract. Compounds are tested in physiological buffers and gastrointestinal fluids to maximize oral bioavailability. [7] [8] [9] [10] [11] At the stage of development of parenteral formulations, the development candidates need to possess good stability and compatibility with different excipients in the formulated solutions to be successful in the clinic. 12, 13 Another important application of solution stability is prodrug screening, in which large numbers of prodrugs are tested in different physiological fluids to select the candidate with the most desirable properties. [14] [15] [16] Traditionally, solution stability studies are performed manually. A major limitation in developing a high-throughput solution stability assay is developing an effective way to quench the reaction. Reactions can continue if they are not stopped. High-throughput stability assays for enzymatic reactions in biological matrices, such as microsomes or plasma, can be stopped by adding organic solvents (e.g., acetonitrile) to the solution to denature the proteins. [17] [18] [19] The samples can then be analyzed using liquid chromatography-mass spectrometry (LC-MS), and the time taken to analyze the samples will not affect the stability results because the catalytic enzymes are no longer active. Unlike the enzymatic reactions, there is essentially no good way to stop the reaction for solution stability. Compounds are constantly exposed to buffer conditions, even if the buffers are titrated to a neutral pH. The incubation time will lengthen as the samples are waiting in the autosampler to be analyzed. For long-duration stability studies, the time taken to analyze the samples might not be significant enough to make a major difference in the incubation time (hours vs. weeks). However, for short-duration stability studies that mimic gastrointestinal transit time or in vitro assay conditions, the time taken to analyze the samples can add a significant portion to the in-cubation time. This will result in relatively shorter incubation time for samples analyzed earlier and relatively longer incubation time for samples analyzed later.
Two traditional approaches are typically used to overcome this challenge. One is to start the incubation of each sample in the buffer at a different time right before the time 0 injection. This spaces the samples by high-performance liquid chromatography (HPLC) run time so that they will end up with a similar incubation time at the end of incubation, and the exact time 0 for each sample is recorded. The 2nd approach is to prepare all the samples in buffers at the same time and start the incubation. After the reaction, all the samples are frozen immediately at -80°C to stop the reaction. The samples are thawed one by one right before analysis, so that they will not have a prolonged exposure time. 20 Both approaches require manual operation. One solution to this may be multichannel analysis systems that simultaneously analyze 24 samples. 21 This would allow studies of solution stability for 24 compounds or 24 buffer conditions at the same time, but most labs do not have this instrumentation. However, many labs do have automated HPLC and LC-MS systems, such as those used for drug development studies, combinatorial synthesis monitoring, and bioanalysis. [22] [23] [24] [25] [26] [27] [28] [29] So far, there are no reports of using an HPLC autosampler for online sample addition, buffer addition, incubation, and injection or to quantitate the stability of drug candidates.
In this article, we discuss the development of an automated method for solution stability studies. The method uses an HPLC autosampler to deliver compounds to the assay matrix and mix them right before time 0 injection. This approach eliminates manual operations for sample preparation. The samples are prepared automatically between injections. The exact time 0 is recorded for each sample. The samples are incubated in the temperaturecontrolled autosampler at a temperature selected by the analyst, and the software is programmed to analyze each sample at any selected time point, based on the experimental design. The method is flexible and can be adapted to many HPLC conditions. It can handle 96 samples and multiple assay conditions simultaneously. The assay is robust, reproducible, and easy to use. Once it is set up, the system requires minimal analyst intervention. The automated sample preparation allows samples to be studied overnight, over the weekend, and on holidays to increase throughput. The method can be applied to screen the stability of compounds in assay buffers, physiological fluids, and formulation vehicles in drug discovery and development.
EXPERIMENTAL

Materials
All reagents used were of the highest grade commercially available. The compounds were obtained from Aldrich and Sigma Chemical Co. (St. Louis, MO) and Fluka (Ronkonkoma, NY); Wyeth compounds were obtained from Wyeth Research (Princeton, NJ).
Instrumentation and software
The HPLC system was an HP1100 with photo diode array detector and temperature-controlled autosampler (Agilent Technologies, Piscataway, NJ). The instrument was controlled by ChemStation ® software (version Rev.A.09.01). Kinetic analysis was performed using Scientist ® software (version 1.01).
HPLC separation conditions
The HPLC method, used for all the analyses reported in this article, unless specified otherwise, was as follows: 
Data processing
Data generated from instruments were explored to excel for data processing and calculation. The percentage remaining was calculated by dividing the area at a specific time point with the area at time 0. The data were loaded to a corporate database using costume-written software and macros. Provisions for data processing reduce the burden on the analyst.
Stability procedure
In a typical experiment, unless otherwise specified, the buffer plate was prepared by adding 180 µL of buffer to the 0.5-mL wells of a 96-deep-well plate (Corning Incorporated, Corning, NY). The deep-well plate was sealed with a resealable plate mat (National Scientific Company, Duluth, GA) and centrifuged at 3000 rpm for 10 min to spin down any liquid adhering to the wall of the wells. The sample plate was prepared by adding 100 µL of DMSO sample stock solution at 1 mg/mL to the appropriate 300-µL wells of a 96-shallow-well plate (Corning Incorporated). The sample plate was sealed with a resealable plate map. Both the sample plate and the buffer plate were placed into the temperature-controlled HPLC autosampler and equilibrated for at least 10 min. The temperature accuracy is ±1°C.
Preparation of the incubation plate was automatically performed using the HPLC autosampler with an injection program (see Table 1 ). The autosampler syringe drew 20 µL of the sample Automated Solution Stability Assay for Drug Discovery stock from the sample plate and ejected it into the buffer plate. The autosampler syringe mixed the solution 3 times with a 100 µL volume. During mixing, the autosampler syringe drew 100 µL from 0 mm offset with a speed of 200 µL/min and ejected at 7 mm offset at 500 µL/min and repeated 3 times. After mixing, the sample loop was flushed with 90% (0.1% formic acid in ACN)/10% (0.1% formic acid in water) for 0.5 min at 3 mL/min to waste (position 1 of the 6-port valve in Fig. 1a ). The 6-port valve was then switched to position 2 ( Fig. 1b) , where the column was equilibrated with 100% A (0.1% formic acid in water) for 1 min at a flow rate of 0.8 mL/ min. The incubated sample was injected into the HPLC column with the standard autosampler injection program. The sample from the incubation plate was injected at subsequent time points to monitor the stability of the compound in the solution over a period of time. The process was controlled by the autosampler program sequence. An example is shown in Table 2 . The temperature of the autosampler compartment was controlled by the software and could be set over the range of 4°C to 40°C, allowing for a wide range of incubation conditions as needed for a particular study.
Optimization of mixing conditions
Theophylline was dissolved in DMSO at 1 mg/mL and placed in the sample plate. Theophylline stock was delivered to the 180 µL phosphate buffered saline (PBS; without Ca and Mg, pH 7.4) buffer plate using the stability procedure above and mixed using either 1) a fixed position for 3 times or 2) up-down movement (as in the injector program in Table 1 ). The incubation plate samples were injected 15 times onto the HPLC column for analysis to de-termine the thoroughness of the mixing using these 2 different methods.
Stability in biological assay buffer
Ninety-six Wyeth samples from an ongoing research program were dissolved in DMSO at 1 mg/mL, and 100 µL of each sample was added to the respective wells of a 96-shallow-well plate to make a sample plate. Assay buffer (180 µL) was added to each of the 96 deep wells to make a buffer plate. The assay buffer contained 20 mM N-[2-Hydroxyethyl]piperazine-N′-[2-ethane sulfonic acid] pH 7.2, 100 mM NaCl, 0.1% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propane-sulfonate, 10% sucrose, and 1 mM EDTA. The incubation plate was prepared and Et cetera A "wait" method was created with low flow rate and 30 min run time. It was inserted between runs when no injection was needed. a. The details on each method are shown in Table 3 . incubated according to the stability procedure above. The samples were injected at time 0 and again at 21 h to monitor the stability of the compounds in assay buffer at 25°C. To determine whether the compounds precipitated during the study, 20 µL of the DMSO stock solution was added to 180 µL of the assay buffer in clear vials. Precipitation was recorded based on visual inspection.
Stability in pH buffers and physiological fluids
Five pH values, 1, 4.5, 6.6, 7.4, and 9.0, were selected. Aqueous pHs were established at 0.1 M using the following buffers: HCl (pH 1.0), sodium acetate (pH 4.5), potassium phosphate (pH 6.6 and pH 7.4), and sodium boric acid (pH 9.0), and the ionic strength was adjusted to 0.20 M using NaCl. Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared according to U.S. Pharmacopeia specifications. 30 Each different buffer or simulated fluid was placed in different wells of the buffer plate. Sample stock was transferred from the sample plate to a particular buffer well and mixed just before the time 0 injection. Stability experiments were started in subsequent buffers in sequence thereafter, as shown in Table 2 . The reaction mixture in the incubation well was then injected at regular time intervals according to the sequence. Thus, the experiments under different incubation conditions were interspersed. A Wyeth research compound containing a β-lactam moiety was dissolved in DMSO at 10 mM. It was incubated according to the stability procedure above, except that 5 µL of DMSO stock was added to 195 µL of the 5 different pH buffers. The incubation plate was incubated at room temperature, and sam-ples were injected periodically for about 35 h. The same experiment was performed using bisacodyl. The hydrolysis products of bisacodyl were identified using LC-MS with electrospray ionisation (Waters ZQ, Milford, MA). The same experiment was performed for vincamine using 1 mg/mL (±)-1-(1-naphthyl)-ethanol internal standard to minimize the effects of evaporation. The stability procedure above was used with the pH buffers, SGF, and SIF, with the exception of adding 25 µL stock into 225 µL buffer and 10 µL injection volume. Vincamine was incubated at 37°C for about 25 h with periodic injections.
RESULTS AND DISCUSSION
The automated solution stability method uses the flexibility of the HPLC system to accurately deliver, mix, incubate, and analyze the samples within a single system. This greatly increases efficiency and reduces manual operation. A schematic diagram of the method is shown in Figure 2 .
Optimization of experimental conditions
Complete mixing of sample solution and buffer is very important to produce meaningful results because stability data are calculated based on the response of the analyte. Two modes of mixing were tested by adding 20 µL of 1 mg/mL DMSO solution of theophylline to 180 µL PBS. The default mix function of the instrument mixes the sample by drawing and ejecting the solution at a fixed position. We found that this mode of mixing had low effi-ciency because the solution essentially stayed in the same vicinity. With the same volume of drawing and ejecting, but moving the injector needle up and down, the mixing is much more effective. The results comparing these 2 modes of mixing are shown in Figure 3 . The mixing at a fixed position was incomplete. The concentration of sample remained variable after 15 injections (Fig. 3a) . Mixing with an up-down motion was quite effective. The drawing is at 0 mm offset, and the ejecting is at 7 mm offset (see Table 1 for injector program). We found that 3-times mixing of 100 µL is sufficient for 200 µL of volume (Fig. 3b) .
Several preliminary studies indicated that the system was not able to clean itself after sample delivery and mixing during preparation of the incubation plate. Severe carryover was observed when either buffer was added to samples or the sample was added to the buffer. A flush step with high organic content was added after preparation of the incubation plate and before periodic injections to ensure that the injector and sample loop were clean and without carryover. A 0.5-min flush at 3 mL/min with 0.1% formic acid in 90% acetonitrile/10% water through a union eliminated carryover (position 1 in Fig. 1a) . After flushing, the 6-port valve was switched to position 2 in Figure 1b . The column was equilibrated for 1 min before sample injection ( Table 3 ). The sample was injected at any desired time point to monitor the stability of the compound. For the next sample, the same procedure was repeated. The method was very flexible and can be adapted to many HPLC conditions, whether they are a 5-min run or a 30-min run. A short gradient is effective to screen a large number of compounds. A long gradient is useful to separate closely eluting degradation products (e.g., cis/trans isomers). The use of multiple detection wavelengths (diode array detector) is recommended to cover a wide range of chromophores from the degradents. When feasible, a serial MS detector is highly recommended to gain confidence on sample integrity. The process is controlled by the sample sequence designed by the analyst. Once the sequence is designed, it can be used as a template for subsequent studies.
Screening of drug discovery compounds in biological assay buffer
In drug discovery, compound stability in assay buffers affects biological activity. If a compound is not stable in the assay buffer, the assay results will not be very meaningful. The automated stability method can be used to study the compounds in assay media and allow the teams to integrate activity data with stability information. The stability screening of 96 Wyeth Research compounds from an ongoing project was used to demonstrate this application. The compounds were from the same series containing a labile functional group, which was susceptible for nucleophilic attack from water. The compounds were automatically delivered to the assay buffer, mixed, and injected into the HPLC as described above. The assay rapidly evaluated the stability of the compounds. Similar conditions were set up in clear vials to monitor precipitation of the compounds. Several compounds showed precipitation in the assay buffer. For the compounds that showed precipitation, the stability results were compromised. The percentage of remaining results for the compounds showed that precipitation was likely due to the contribution of both degradation and precipitation. The assay determined the percentage of compounds available in solution for biological activity. The stability screening results of the compounds in an enzyme assay buffer were performed after 21-h incubation at 25°C. This condition was typically used to conduct serial dilution of the compounds before screening for biological activity. About 25% of the compounds showed rapid degradation/ precipitation in the assay buffer, with less than 20% remaining after a 21-h incubation. Selected compounds had been studied using a traditional manual method to confirm the findings. Most compounds were hydrated and rearranged to different products. This example illustrates that the method can be used to quickly evaluate large numbers of compounds in the assay matrix. The information is very helpful for medicinal chemists to develop a structure-activity relationship on stable compounds. If needed, a half-life could be calculated using an approach similar to that used in a previous article. 18
Determination of stability-pH profile and stability in physiological fluids of drug-discovery candidates
A stability-pH profile of drug candidates is very important in selecting the best assay conditions, designing synthetic and purification strategies, developing the optimal formulation, and predicting the oral absorption profile. [31] [32] [33] [34] The automated solution stability method can be applied to determine a stability-pH profile of drug candidates. Three compounds were used to prototype the applications, including a β-lactam from a Wyeth Research project and 2 commercial drugs, bisacodyl and vincamine. The stability of the commercial compounds in different pHs and physiological fluids is shown in Figures 4 and 5 . When performing solution stability at elevated temperature, evaporation of solvents can result in a higher concentration of the compound in solution and artificially higher percentage remaining. Two approaches are taken to minimize the effect: 1) use of a resealable mat to minimize loss of solvents and 2) use of internal standard to compensate for the evaporation of solvents. The stability of vincamine was determined at elevated temperature (37°C). Internal standard [(±)-1-(1-naphthyl)-ethanol] was used to compensate for evaporation. No significant impact on the results due to evaporation was observed. The chromatograms and hydrolytic products of bisacodyl and vincamine are shown in Figures 6 and 7, respectively , as examples. The data were analyzed by using pseudo 1st-order irreversible kinetics. The assay rapidly evaluates the stability of compounds and determines kinetic parameters, such as half-life. The HPLC readily couples to a mass spectrometer, allowing rapid identification of degradation products to follow their kinetics and determine mechanisms of formation. The information can be used to guide decision making at different stages of drug discovery and development.
CONCLUSIONS
An automated solution stability method has been developed. It takes advantage of the advanced capabilities of HPLC autosamplers by using them to perform the following steps while unattended: add up to 96 different compounds to stability test solutions, add various test solutions to up to 96 different compounds, mix, incubate the solutions at a selected temperature, sample solutions at preprogrammed time points, and inject samples onto the HPLC system. Although the autosampler from 1 widely distributed manufacturer has been used, the protocol is adaptable to other systems having the ability to dispense sample and preprogram commands. The approach is robust, reproducible, and easy to use. It allows experiments to be automated for 96 compounds at a time with only about 0.5 h of a scientist's time, as opposed to 8 h of time necessary for manual methods. The method has many applications in drug discovery, including screening compound stability in assay media, providing a stability-pH profile, testing stability in physiological fluids, checking excipient compatibility, and performing forced degradation studies. The method has been used to screen compound stability and study the kinetics of compound degradation and degradant formation. This approach can also be applied in drug development to investigate the stability of development candidates.
